Yonsa is owned by Sun Pharm.
Yonsa contains Abiraterone Acetate.
Yonsa has a total of 2 drug patents out of which 0 drug patents have expired.
Yonsa was authorised for market use on 22 May, 2018.
Yonsa is available in tablet;oral dosage forms.
Yonsa can be used as use in combination with methylprednisolone for the treatment of patients with prostate cancer.
The generics of Yonsa are possible to be released after 20 May, 2034.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9889144||SUN PHARM||Abiraterone acetate formulation and methods of use|| |
(10 years from now)
|US10292990||SUN PHARM||Abiraterone steroid formulation|| |
(11 years from now)
Drugs and Companies using ABIRATERONE ACETATE ingredient
Market Authorisation Date: 22 May, 2018
Treatment: Use in combination with methylprednisolone for the treatment of patients with prostate cancer
Korea, Republic of
Taiwan, Province of China
Moldova, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic